Hibiscus flower extract selectively induces apoptosis in breast cancer cells and positively interacts with common chemotherapeutics.
Adjuvant therapy
Apoptosis
Breast cancer
Chemotherapeutic interactions
Cisplatin
Hibiscus
Natural health products
Tamoxifen
Taxol
Journal
BMC complementary and alternative medicine
ISSN: 1472-6882
Titre abrégé: BMC Complement Altern Med
Pays: England
ID NLM: 101088661
Informations de publication
Date de publication:
06 May 2019
06 May 2019
Historique:
received:
17
01
2019
accepted:
16
04
2019
entrez:
8
5
2019
pubmed:
8
5
2019
medline:
18
6
2019
Statut:
epublish
Résumé
Current therapeutic approaches to treat metastatic breast cancer, although effective, have shown many inadvertent side effects such as genotoxicity due to a lack of selectivity. Thus, these treatment plans are not suitable for long-term usage. Natural health product extracts are safe for long-term consumption and some have shown to be medicinally active containing multiple bioactive compounds able target multiple vulnerabilities in cancer. One of which, Hibiscus rosa-sinesis (hibiscus) extract, has been reported to have many medicinal and anticancer properties due to its antioxidant and hypolipidemic effects. However, its efficacy against breast cancer has not been fully investigated and characterized. If effective against cancer, hibiscus extract could potentially be combined with chemotherapeutic treatments in adjuvant therapy to reduce chemotherapy-inducing side effects. We have investigated aqueous hibiscus flower extract anticancer efficacy, selectivity, and interactions with chemotherapeutics taxol, cisplatin, and tamoxifen in estrogen-receptor positive breast cancer cells, triple-negative human breast cancer cells, and normal non-cancerous cells. Apoptotic morphology and biochemical marker expression were assessed to determine the extent anticancer efficacy of hibiscus. Mitochondrial membrane potential reduction and reactive oxygen species generation were quantified using fluorogenic dyes to determine the mechanism of hibiscus extract action. Hibiscus extract was able to selectively induce apoptosis in both triple-negative and estrogen-receptor positive breast cancer cells in a dosage-dependent manner. Most importantly, addition of hibiscus extract was found to enhance the induction of apoptosis of chemotherapy treatments (taxol and cisplatin) in triple-negative breast cancer cells when compared to treatment alone. Moreover, hibiscus extract addition to chemotherapy treatment was able to increase oxidative stress and decrease mitochondrial membrane potential compared to individual treatments. Hibiscus extract is effective on breast cancer, most notably on generally resistant triple-negative breast cancer, while being selective for normal healthy cells. Hibiscus extract could supplement chemotherapeutic regimens as an adjuvant and lead to a more efficacious treatment approach to reduce chemotherapy dosages and related toxicity.
Sections du résumé
BACKGROUND
BACKGROUND
Current therapeutic approaches to treat metastatic breast cancer, although effective, have shown many inadvertent side effects such as genotoxicity due to a lack of selectivity. Thus, these treatment plans are not suitable for long-term usage. Natural health product extracts are safe for long-term consumption and some have shown to be medicinally active containing multiple bioactive compounds able target multiple vulnerabilities in cancer. One of which, Hibiscus rosa-sinesis (hibiscus) extract, has been reported to have many medicinal and anticancer properties due to its antioxidant and hypolipidemic effects. However, its efficacy against breast cancer has not been fully investigated and characterized. If effective against cancer, hibiscus extract could potentially be combined with chemotherapeutic treatments in adjuvant therapy to reduce chemotherapy-inducing side effects.
METHOD
METHODS
We have investigated aqueous hibiscus flower extract anticancer efficacy, selectivity, and interactions with chemotherapeutics taxol, cisplatin, and tamoxifen in estrogen-receptor positive breast cancer cells, triple-negative human breast cancer cells, and normal non-cancerous cells. Apoptotic morphology and biochemical marker expression were assessed to determine the extent anticancer efficacy of hibiscus. Mitochondrial membrane potential reduction and reactive oxygen species generation were quantified using fluorogenic dyes to determine the mechanism of hibiscus extract action.
RESULTS
RESULTS
Hibiscus extract was able to selectively induce apoptosis in both triple-negative and estrogen-receptor positive breast cancer cells in a dosage-dependent manner. Most importantly, addition of hibiscus extract was found to enhance the induction of apoptosis of chemotherapy treatments (taxol and cisplatin) in triple-negative breast cancer cells when compared to treatment alone. Moreover, hibiscus extract addition to chemotherapy treatment was able to increase oxidative stress and decrease mitochondrial membrane potential compared to individual treatments.
CONCLUSION
CONCLUSIONS
Hibiscus extract is effective on breast cancer, most notably on generally resistant triple-negative breast cancer, while being selective for normal healthy cells. Hibiscus extract could supplement chemotherapeutic regimens as an adjuvant and lead to a more efficacious treatment approach to reduce chemotherapy dosages and related toxicity.
Identifiants
pubmed: 31060537
doi: 10.1186/s12906-019-2505-9
pii: 10.1186/s12906-019-2505-9
pmc: PMC6503386
doi:
Substances chimiques
Antineoplastic Agents
0
Plant Extracts
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
98Subventions
Organisme : Lotte and John Hecht Memorial Foundation
ID : 811340
Organisme : Jesse and Julie Rasch Foundation
ID : 813333
Références
J Ethnopharmacol. 1999 Jun;65(3):231-6
pubmed: 10404421
Biochem Pharmacol. 2000 Aug 1;60(3):307-15
pubmed: 10856425
Arch Pathol Lab Med. 2000 Jul;124(7):966-78
pubmed: 10888772
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Nat Rev Cancer. 2005 Aug;5(8):591-602
pubmed: 16056258
Chem Biol Interact. 2007 Jan 5;165(1):59-75
pubmed: 17145051
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
pubmed: 17438091
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Ann Intern Med. 2008 May 6;148(9):671-9
pubmed: 18458280
Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243
pubmed: 18980022
Indian J Exp Biol. 2009 Apr;47(4):276-82
pubmed: 19382724
Annu Rev Genet. 2009;43:95-118
pubmed: 19659442
Ann Intern Med. 2009 Nov 17;151(10):727-37, W237-42
pubmed: 19920273
Nat Rev Urol. 2010 Jan;7(1):21-30
pubmed: 19997071
J Exp Clin Cancer Res. 2011 Sep 26;30:87
pubmed: 21943236
Sci Transl Med. 2014 Mar 26;6(229):229ra43
pubmed: 24670687
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
World J Clin Oncol. 2014 Aug 10;5(3):283-98
pubmed: 25114845
Mol Biol Cell. 2014 Sep 15;25(18):2677-81
pubmed: 25213191
PLoS One. 2014 Nov 17;9(11):e113250
pubmed: 25401766
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Evid Based Complement Alternat Med. 2015;2015:751348
pubmed: 25883673
BMC Complement Altern Med. 2015 Mar 14;15:65
pubmed: 25885960
Nutrients. 2015 Jun 24;7(7):5065-87
pubmed: 26115086
Food Funct. 2015 Sep;6(9):2957-66
pubmed: 26234931
Breast Cancer (Auckl). 2015 Sep 27;9(Suppl 2):17-34
pubmed: 26462242
Cell Death Dis. 2016 Jun 09;7(6):e2253
pubmed: 27277675
Breast Cancer (Dove Med Press). 2016 May 20;8:93-107
pubmed: 27284266
Oncotarget. 2016 Nov 8;7(45):73080-73100
pubmed: 27564258
Nutr Cancer. 2016 Oct;68(7):1161-70
pubmed: 27618152
Oncotarget. 2017 Jan 3;8(1):1913-1924
pubmed: 27765921
Nutrients. 2017 Aug 20;9(8):null
pubmed: 28825642
Oncotarget. 2017 Nov 18;8(67):110756-110773
pubmed: 29340014